A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Hutchmed
PharmaMar
Hoffmann-La Roche
Imperial College London
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Medical University Innsbruck
Peking Union Medical College Hospital
Ipsen
Molecular Insight Pharmaceuticals, Inc.